Drug Trial Radar · NCT02145338
Antibiotic Prophylaxis for Clean Intermittent Catheterisation
Last checked: Nov 19, 2026Latest source record: Mar 30, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
404
Actual
Start
Sep 2013
Primary completion
Feb 22, 2017
Study completion Feb 22, 2017
Sponsor
- Lead sponsor
- Newcastle-upon-Tyne Hospitals NHS TrustAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- NHS Health Technology Assessment Programme; Newcastle University; Glasgow Caledonian University; University of Aberdeen; Cambridge University Hospitals NHS Foundation Trust; North Bristol NHS Trust; University of Southampton
- First posted
- May 22, 2014
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This research project is designed to find out whether people who suffer repeated urinary tract infections (UTI) related to the need to empty their bladders intermittently with a fine plastic tube (catheter); a process called clean intermittent self-catheterisation (CISC), benefit from taking continuous daily low-dose antibiotics (antibiotic prophylaxis). The investigators estimate that about 40,000 people in the United Kingdom need to use CISC regularly to empty their bladder either because of nerve damage such as multiple sclerosis or because of failure of the bladder muscle to contract, and of these about 25% (10,000 people) suffer frequent UTI. One way to reduce this problem may be to take a small daily dose of antibiotics and the study aims to find out whether such treatment is effective and worthwhile both for the people who suffer the problem and for the National Health Service (NHS). The two options to be compared in the trial are firstly, a once daily preventive dose (prophylaxis) of an antibiotic routinely used for this purpose (either nitrofurantoin or trimethoprim or cefalexin), and secondly no prophylaxis. The investigators think that an overall decrease of 20% or more in the frequency of UTI would be large enough for future patients using CISC who get troublesome recurrent UTIs to be offered antibiotic prophylaxis routinely. The investigators will also assess any harm caused by continuous use of antibiotics, particularly side effects for those people taking them and changes in the resistance of bacteria to these antibiotics. The investigators can then work out whether the balance between the benefits and harms make the use of prophylaxis worthwhile to people carrying out CISC and for the NHS as a whole.
Conditions
- Urinary Tract Infections, Recurrent
Interventions
Nitrofurantoin or Trimethoprim or CefalexinDrug
Antibiotic prophylaxis
No prophylaxisOther
Discrete treatment courses of antibiotics as indicated by symptoms or signs of UTI.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Relative incidence of symptomatic antibiotic-treated UTITime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institute of Cellular Medicine, Newcastle University
Newcastle upon Tyne, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.